SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Satchel Paige

PatientSatchel Paige
Date of birth1953-07-07
IdentifiersMRN HR-ML047-SYN; SSN (made up) 000-47-3381
Document date2026-10-27
AuthorDelphine Whitaker-Osei, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Fifteen-week review after an exacerbation and pulmonary rehabilitation. [S]

History of Present Illness

Mr. Paige returns five weeks after a moderate exacerbation treated at home with prednisone and doxycycline, and five days after finishing pulmonary rehabilitation (twenty sessions). He used his action plan well: he called the clinic the morning his breathing worsened and started treatment that day. He is back to walking to the store and beyond without stopping and uses albuterol about twice a week. He takes his inhaler every morning. He had his vaccines at the wellness visit three weeks ago with only a sore arm. His aortic ultrasound a week ago showed no aneurysm, and his hepatitis C and hepatitis B tests were negative. He asked whether he needs another inhaler after the flare-up. [S]

ElementDetail
SymptomsCAT 11; mMRC 1
ExacerbationsOne moderate, five weeks ago, treated at home; no hospital stay
Six-minute walk425 m, from 360; lowest saturation 92 percent
MoodPHQ-9 2
Screening resultsAorta 2.4 cm; hepatitis C and B negative

Review of Systems

SystemResultFinding
RespiratoryPositiveUsual mild breathlessness on hills; little sputum; no wheeze
CardiovascularNegativeNo chest pain, palpitations or ankle swelling
MusculoskeletalNegativeNo muscle aches
PsychiatricNegativeMood good; PHQ-9 2

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Albuterol 90 micrograms per inhalation metered-dose inhaler with a spacer, two inhalations every four hours as needed for breathlessnessTwo inhalations with a spacer every 4 hours as neededRespiratory tract route2026-07-14activeS
Umeclidinium 62.5 micrograms with vilanterol 25 micrograms dry powder inhaler (a LAMA with a LABA), one inhalation once a dayOne inhalation each morning; a strong, deep breath inRespiratory tract route2026-07-28activeS
Atorvastatin 20 mg tablet once a dayOne tablet each eveningOral route2026-07-14activeS
Prednisone 40 mg (two 20 mg tablets) by mouth each morning for five daysTwo tablets each morning with food for five daysOral route2026-09-22 to 2026-09-26completedS
Doxycycline 100 mg capsule by mouth twice a day for five daysOne capsule twice a day with a full glass of water, sitting up, for five daysOral route2026-09-22 to 2026-09-26completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-27Body height191cmS
2026-10-27Body weight83.4kgS
2026-10-27Body mass index (BMI) [Ratio]22.9kg/m2S
2026-10-27Systolic blood pressure128mm[Hg]S
2026-10-27Diastolic blood pressure78mm[Hg]S
2026-10-27Heart rate76/minS
2026-10-27Respiratory rate16/minS
2026-10-27Body temperature36.6CelS
2026-10-27Oxygen saturation in Arterial blood by Pulse oximetry95%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-27Six minute walk test425mPredicted about 520 m for his age, sex and height; lower limit about 400 mNormalS
2026-10-27Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]2{score}S

Physical Exam

Vital signs recorded on 2026-10-27; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 128/78, pulse 76, oxygen saturation 95 percent on room air
RespiratoryReduced breath sounds; no wheeze or crackles
CardiovascularRegular rhythm; no edema
Inhaler techniqueCorrect

Problems

ProblemClinical statusVerificationCodeProvenance
Breathlessness on exertion for about two years, now after one flight of stairs or a block on the level (mMRC 2), with a morning cough and a little clear sputum most days; no chest pain, ankle swelling, orthopnea, wheeze at rest or weight loss; a former smoker of about 30 pack-years; cause under evaluation with spirometry and a pulmonology consultationresolvedconfirmed R06.09S — Synthetic presenting problem anchored to his documented emphysema; superseded when spirometry at the consultation confirmed COPD.
Chronic obstructive pulmonary disease, GOLD grade 2 (post-bronchodilator FEV1/FVC 0.58, FEV1 61% predicted by the race-neutral GLI Global equations), GOLD group B (CAT 18, mMRC 2, no exacerbation in the past year); alpha-1 antitrypsin normal; blood eosinophils 0.08 x 10^3/uL; synthetic modern diagnosis linked to his documented emphysemaactiveconfirmed J44.9S — Synthetic modern diagnosis made at the consultation, anchored to his documented emphysema; its onset and course in the modern episode are synthetic.
Former cigarette smoker, about 30 pack-years, stopped eleven years ago on his own; no use sinceactiveconfirmed Z87.891S — Synthetic smoking history: whether he smoked is not documented in the sources read, so the history is synthetic and labeled as such.
Hyperlipidemia: LDL 148 mg/dL, HDL 44 and triglycerides 160 at intake; estimated 10-year cardiovascular risk about 18 percent; atorvastatin started by shared decisionactiveconfirmed E78.5S — Synthetic cardiovascular risk factor anchored to his documented heart trouble; not a claim about his real lipids.
Moderate exacerbation of COPD with a viral cold: more breathlessness, more sputum turning green, and wheeze for three days; oxygen saturation 92 percent; no pneumonia on chest X-ray; treated at home with prednisone and doxycycline; recoveredresolvedconfirmed J44.1S — Synthetic exacerbation at the sick visit; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveySymptoms: CAT and mMRC dyspnea scaleEvery visitCompleted todayCAT 11; mMRC 1
SurveyExacerbations in the past 12 months (moderate and severe) and GOLD groupEvery visitCompleted todayOne moderate exacerbation in the past year; still group B
ExaminationPulse oximetry at restEvery visitCompleted today95 percent on room air
LaboratorySpirometry: post-bronchodilator FEV1/FVC and FEV1 % predicted (race-neutral GLI Global)At diagnosis, then at least yearly or with a clear changeUp to dateNext spirometry in the summer, a year after diagnosis
LaboratoryBlood eosinophil countAt baseline and when an inhaled corticosteroid is consideredUp to date0.08 x 10^3/uL at intake; an inhaled corticosteroid considered after the exacerbation and not advised
Self-managementSmoking status and cessation supportEvery visitCompleted todaySmoke-free
ExaminationBMI and nutritionEvery visitCompleted todayBMI 22.9; weight steady after the steroid course
Medication safetyInhaler technique, adherence and side effects (dry mouth, urinary retention)Every visitCompleted todayCorrect technique; no missed doses
ExaminationECG and cardiovascular riskAt baseline; reassess after exacerbationsDeferredThe ECG that the CMID protocol calls for after an exacerbation was not done at the sick visit. He has had no chest pain or palpitations, and today's ECG is unchanged from intake, so no harm is evident. Corrective action: ECG done today and added to the clinic's exacerbation visit template
ReferralPulmonary rehabilitationOffer when mMRC is 2 or more, or CAT 10 or more; within three weeks of a hospital discharge for an exacerbationCompleted todayTwenty sessions completed five days ago; maintenance class and home program
ExaminationSix-minute walk testAt rehabilitation entry and exit, and for oxygen assessmentCompleted today425 m at rehabilitation exit; lowest saturation 92 percent
ExaminationLong-term oxygen assessmentWhen resting PaO2 is 55 mm Hg or less (60 with cor pulmonale or polycythemia) or saturation 88 percent or less, confirmed twiceNot indicatedSaturation 95 percent at rest and 92 percent at its lowest on walking
Self-managementWritten and spoken COPD action planAt diagnosis, reviewed after each exacerbationCompleted todayUsed well at the exacerbation; reviewed
Self-managementVaccines: influenza, pneumococcal, RSV, COVID-19, Tdap, zosterYearly reviewUp to dateInfluenza, RSV, COVID-19 and the first zoster dose three weeks ago; PCV20 and Tdap at intake; second zoster dose due
ImagingLow-dose CT lung cancer screeningYearly at 50 to 80 with 20 or more pack-years, while within fifteen years of quittingUp to dateNext in the summer
Medication safetyStatin safety: muscle symptomsEvery visitCompleted todayNo muscle aches
SurveyMood (PHQ-9)At intake and when symptoms changeCompleted today2, from 5, with item 9 scored 0

Goal progress:

Guideline basis: Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025); Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement (2023); CMID: Clinical Monitoring Intelligence Database, COPD and hyperlipidemia monographs (2026); Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023); Home Oxygen Therapy for Adults with Chronic Lung Disease: An Official American Thoracic Society Clinical Practice Guideline (2020); A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation (LOTT) (2016); Racial Bias in Pulse Oximetry Measurement (2020); Lung Cancer: Screening (2021); Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (2022); Adult Immunization Schedule by Age (2026); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Review in three months, sooner for a flare. Spirometry and low-dose CT next summer. Second zoster dose in one to five months. Next wellness visit in a year. [S]